Arvinas schedules first zaloblideg Phase 1 findings for ASH
Company / institutional announcement · Arvinas
Source published: · Event / reporting date: 2026-11-04
Site published: 2026-11-05 · Updated: 2026-11-05
This source is linked automatically. Choose a question to get started.
What changed
Arvinas announced an ASH poster on preliminary Phase 1 findings for oral BCL6 degrader ARV-393, also called zaloblideg, in relapsed or refractory non-Hodgkin lymphoma. The December 14 presentation will cover safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in T-cell lymphomas. The announcement itself does not provide numerical response results.
Why it may matter
Analysis: Human BCL6 degradation data may guide target-validation priorities; an early dose-escalation presentation cannot establish comparative efficacy.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections